Anti-Mullerian hormone and polycystic ovary syndrome

封面


如何引用文章

全文:

详细

Polycystic ovary syndrome (PCOS) is the most common form of normogonadotropic ovarian insufficiency, hyperandrogenaemy and anovulation sterility. One of the probable causes of this disease is disturbance of folliculogenesis, which is accompanied by overproduction of anti-Mullerian hormone (AMH) by ovarian tissue. There is a literature review about structure, biological properties and the role of AMH in pathogenesis of PCOS in this article.

作者简介

Igor Nikolaenkov

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: Nikolaenkov_igor@mail.ru
PhD student

Vladimir Potin

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: iagmail@ott.ru
PhD, Honoured figure, professor, Head of Gynecological Endocrinilogy Department

Marina Tarasova

D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS

Email: tarasova@ott.ru
MD, PhD, specialist, professor

参考

  1. Бебия З. Н., Орлов В. М. Антимюллеровый фактор. Журнал акушерства и женских болезней. 1999; 2: 66-70.
  2. Боярский К. Ю., Гайдуков С. Н. Роль антимюллерова гормона (АМГ) в норме и при различных гинекологических заболеваниях. Журнал акушерства и женских болезней. 2009; 3: 74-83.
  3. Дедов И. И., Г. А. Мельниченко, Т. В. Чеботникова и др. Распространенность и клиническая картина синдрома поликистозных яичников в популяции Москвы. Клиническая эндокринология. 2010; 4: 7-8.
  4. Дедов И. И., Мельниченко Г. А. ред. Синдром поликистозных яичников: Руководство для врачей. М.: МИА; 2007.
  5. Лесной С. К. Частичная резекция яичников при олигоменорее и аменорее. Акушерство и гинекология. 1928; 7: 16-19.
  6. Назаренко Т. А. Женское бесплодие, обусловленное нарушениями процесса овуляции (клиника, диагностика, лечение). Автореф. дис. … д-ра мед. наук. М. 1998.
  7. Al-Qahtami A., Groome N. Anti-Mullerian hormone: Cinderella finds new admirers. J. Clin. Endocrinol. Metab. 2006; 91: 3760-2.
  8. Arbo E., Vetori D. V., Jimenez M. F. et al. Serum anti-mullerian hormone levels and follicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. Human Reproduction. 2007; 22: 3192-6.
  9. Asuncion M., Calvo R. M., San Millan J. L. et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 2000; 85 (7): 2434-8.
  10. Azziz R., Woods K. S., Reyna R. et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 2004; 89: 2745-9.
  11. Badawy A., Elnashar A. Treatment options for polycystic ovary syndrome. Int. J. Womens Health. 2011; 3: 25-35.
  12. Bayrak A., Terbell H., Urwitz-Lane R. et al. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil. Steril. 2007; 87: 870-5.
  13. Behringer R. R., Finegold M. J., Cate R. L. Müllerian inhibiting substance function during mammalian sexual development. Cell. 1994; 79: 415-25.
  14. Broekmans F. J., Kwee J., Hendriks D. J. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. 2006; 12: 685-718.
  15. Broer S., Mol B. W., Dolleman M. et al. The role of anti-Mullerian hormone assessment in assisted reproductive technology outcome. Curr. Opin. Obstet. Gynecol. 2010; 22: 193-201.
  16. Carlsen S. M., Vanky E., Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum. Reprod. 2009; 24: 1732-8.
  17. Cate R. L., Mattaliano R. J., Hession C. et al. Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell. 1986; 45: 685-98.
  18. Conway G. S., Jacobs H. S. Clinical implications of hyperinsulinaemia in women. Clinical Endocrinology. 1993; 39: 623-32.
  19. Das M., Gillott D. J., Saridogan E., Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary sundrome. Hum. Reprod. 2008; 23: 2122-6.
  20. de Santa Barbara P., Moniot B., Poulat F et al. Steroidogenic Factor-1 regulates transcription of the human anti-Mullerian hormone receptor. J. Biol. Chemistry. 1998; 273 (45): 29654-60.
  21. Deb S., Campbell B. K., Pincott-Allen C. et al. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound. Ultrasound Obstet. Gynecol. 2012; 39 (5): 574-80.
  22. Dólleman M., Verschuren W. M., Eijkemans M. J. et al. Reproductive and lifestyle determinants of anti-Müllerian hormone in a large population-based study. J. Clin. Endocrinol. Metabol. 2013; 98 (5): 2106-15.
  23. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008; 9: 1191-7.
  24. Durlinger A. L., Gruijters M. J., Kramer P. et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002; 143: 1076-84.
  25. Durlinger A. L., Visser J. A., Themmen A. P. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction. 2002; 124: 601-9.
  26. Eldar-Geva T., Margalioth E. J., Gai M. et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women in polycystic ovaries with and without hyperandrogenism. Hum. Reprod. 2005; 20: 1814-9.
  27. Fallat M. E., Cook C., Siow Y., Carrillo A., Marra M. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil. Steril. 1997; 67: 962-5.
  28. Fleming R., Harborne L., MacLaughlin D.T. et al. Metformin reduces serum Mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil. Steril. 2005; 83: 130-6.
  29. Goodarzi M. O., Quinones M. J., Azziz R. et al. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil. Steril. 2005; 84 (3): 766-9.
  30. Grossman M., Nakajima S., Fallat M., Siow Y. Mullerian inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil. Steril. 2008; 89: 1364-70.
  31. Hehenkamp W. J., Looman C. W., Themmen A. P. et al. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin.Endocrinol. Metabol. 2006; 91: 4057-63.
  32. Ji Hee Yoo, Hye Ok Kim, Sun Wha Cha et al. Age specific serum anti-Müllerian hormone levels in 1,298 Korean women with regular menstruation. Clin. Exp. Reprod. Med. 2011; 38 (2): 93-97.
  33. Kallio S., Puurunen J., Ruokonen A. et al. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil. Steril. 2013; 99 (5): 1305-10.
  34. La Marca A., Giulini S., Orvieto R. et al. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum. Reprod. 2005; 20: 1569-72.
  35. La Marca A., Orvieto R., Giulini S. et al. Müllerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil. Steril. 2004; 82: 970-2.
  36. La Marca A., Sighinolfi G., Radi D. et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum. Reprod. 2010; 16: 113-30.
  37. La Marca A., Stabile G., Artenisio A. C., Volpe A. Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum. Reprod. 2006; 21: 3103-7.
  38. La Marca A., Volpe A. Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin. Endocrinol. 2006; 64 (6): 603-10.
  39. Laven J. S.E., Mulders A. M., Visser J. et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metabol. 2004; 89: 318-23.
  40. Lee M. M., Donahoe P. K., Hasegawa T. et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. 1996; 81: 571-6.
  41. Lobo R. A., Carmina E. The importance of diagnosing the polycystic ovary syndrome Ann. Intern. Med. 2000; 132 (12): 989-93.
  42. Masiakos P. T., MacLaughlin D.T., Maheswaran S. et al. Human ovarian cancer, cell lines and primary ascites all express the human Mullerian inhibiting substance (MIS) type II receptor, bind and are responsive to MIS. Clin. Cancer Res. 1999; 5: 3488-99.
  43. Massagué J. The transforming growth factor-b family. Ann. Rev. Cell Biol. 1990; 6: 597-641.
  44. Mohamed K. A., Davies W. A., Lashen H. Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil. Steril. 2006; 86: 1515-7.
  45. Moran L. J., Noakes M., Clifton P. M., Norman R. J. The use of anti-Mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metabol. 2007; 92: 3796-802.
  46. Nakhuda G. S., Chu M. C., Wang J. et al. Elevated serum MIS levels may be a marker for ovarian hyperstimulation syndrome in normal women undergoing IVF. Fertil. Steril. 2006; 85: 1541-3.
  47. Nelson S. M., Yates R. W., Lyall H. et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod. 2009; 24: 867-75.
  48. Nilsson E. E., Schindler R., Savenkova M. I., Skinner M. K. Inhibitory actions of anti-Mullerian hormone (AMH) on ovarian primordial follicle assembly. PLoS One. 2011; 6 (5): 20087.
  49. Pellatt L., Hanna L., Brincat M. et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J. Clin. Endocrinol. Metab. 2007; 92: 240-5.
  50. Pellatt L., Rice S., Mason H. D. Anti-Mullerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010; 139 (5): 825-33.
  51. Pigny P., Merlen E., Robert Y. et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicle arrest. J. Clin. Endocrinol. Metabol. 2003; 88: 5957-62.
  52. Piouka A., Farmakiotis D., Katsikis I. et al. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am. J. Physiol. Endocrinol. Metabol. 2009; 296: 238-43.
  53. Rajperts-de Meyts E., Jorgensen N., Graem N. et al. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J. Clin. Endocrinol. Metabol. 1999; 84: 3836-44.
  54. Rey R., Belville C., Nihoul-Fekete C. et al. Evaluation of gonadal function in 107 intersex patients by means of serum anti-Mullerian hormone measurement. J. Clin. Endocrinol. Metab. 1999; 84: 627-31.
  55. Rey R., Sabourin J. C., Venara M. et al. Anti-Mullerian hormone is specific marker of sertoli- and granulose-cell origin in gonadal tumors. Hum. Pathol. 2000; 31: 1202-3.
  56. Rotterdam E. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81 (1): 19-25.
  57. Seifer D. B., Baker V. L., Leader B. Age-specific serum anti-Mullerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil. Steril. 2011; 95: 747-50.
  58. Stephen A. E., Pearsoll L. A., Christian B. P. et al. Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin. Cancer Res. 2002; 8: 2640-6.
  59. Streuli I., Fraisse T., Chapron C. et al. Clinical uses of anti-Mullerian hormone assays: pitfalls and promises. Fertil. Steril. 2009; 91: 226-30.
  60. Thomson R. L., Buckley J. D., Moran L. J. et al. The effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum. Reprod. 2009; 24: 1976-81.
  61. Van Rooij I. A., Broekmans F. J., te Velde E. R. et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 2002; 17: 3065-71.
  62. Visser J. A., Themmen A. P. Anti-Mullerian hormone and folliculogenesis. Mol. Cell Endocrinol. 2005; 234: 81-6.
  63. Wachs D. S., Coffler M. S., Malcom P. J., Chang R. J. Serum anti-Mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J. Clin. Endocrinol. Metabol. 2007; 92: 1871-14.
  64. Willis D., Mason H., Gilling-Smith C., Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J. Clin.Endocrinol. Metabol. 1996; 81: 302-9.

版权所有 © Nikolaenkov I.P., Potin V.V., Tarasova M.A., 2013

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

##common.cookie##